Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.

We regularly navigate commercial and regulatory issues related to the Food and Drug Administration, the Patent Trade and Appeals Board, the European Medicines Agency, the European Commission, and other state, and federal agencies in the US and across Europe.

We deliver:

  • The right team. We work with companies at every stage of development, from fast-growing startups to mature public companies, in virtually every sector and subsector of the industry – including healthcare services, biotechnology, medtech and medical devices. With an outstanding global platform, we can scale our client teams to meet client needs — whether that means drawing on best-of-the-best capabilities in public company representation, M&A, capital markets, regulatory advice or IP and securities litigation.
  • Insight. Our broad client base and on-the-ground presence in the world’s healthcare and life sciences hubs afford us an expansive view of the commercial, scientific, regulatory, and political trends shaping the markets in which clients operate. We know how traditional regulatory regimes work, and quickly set the bar for successful strategies in dynamic and uncertain regulatory landscapes.
  • Results. By leveraging decades of experience and a culture of innovation, we have developed an impressive track record navigating many of the industry’s largest, most complex, and most consequential deals through commercial and regulatory issues, as well as winning precedent-setting litigation and trials.


Our Experience

Awards & Rankings

  • Marc Jaffe Named Distinguished Leader by New York Law Journal - October 25, 2020
  • Fifteen Partners Receive 2020 MVP Honors - October 04, 2020
  • American College of Trial Lawyers Inducts Partners Max Grant and Joe Serino - September 28, 2020
  • Latham Recognized with Seven Notable Accolades - September 22, 2020
  • Litigation & Trial Partner Named Rising Star in San Diego - September 09, 2020

A best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships. Acts for early-stage and long-established companies as well as banks and financiers. Contentious practice with expertise in handling everything from white-collar investigations to intellectual property disputes. 

Chambers 2020 USA

Media Coverage

Life Sciences MVPs: Latham's Daniel Brown and Kenneth SchulerTop 40 Under 40: Amy Hargreaves


Latham & Watkins Advises Sobi on Strategic Licensing and Collaboration Agreement with Apellis Pharmaceuticals Inc.Latham & Watkins Advises Underwriters in Foghorn Therapeutics’ IPOMarc Jaffe Named Distinguished Leader by New York Law Journal

Thought Leadership

Securities Litigation Trends During Covid-19UK Issues New Guidance for Medical Device Regulation After BrexitHealthcare AI Deals a Tonic for PE Investors